Jafron Biomedical Co.,Ltd.

SZSE:300529 Stock Report

Market Cap: CN¥21.5b

Jafron BiomedicalLtd Past Earnings Performance

Past criteria checks 2/6

Jafron BiomedicalLtd has been growing earnings at an average annual rate of 2.7%, while the Medical Equipment industry saw earnings growing at 6.5% annually. Revenues have been growing at an average rate of 11.2% per year. Jafron BiomedicalLtd's return on equity is 15.9%, and it has net margins of 25.1%.

Key information

2.7%

Earnings growth rate

2.5%

EPS growth rate

Medical Equipment Industry Growth16.0%
Revenue growth rate11.2%
Return on equity15.9%
Net Margin25.1%
Last Earnings Update31 Mar 2024

Recent past performance updates

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

May 02
Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

Recent updates

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

May 28
Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

May 24
A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

May 08
Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

May 02
Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Apr 13
Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Mar 22
Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Mar 04
Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Revenue & Expenses Breakdown

How Jafron BiomedicalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300529 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 242,094525798246
31 Dec 231,922436784245
30 Sep 231,952440826268
30 Jun 231,949419855269
31 Mar 232,367751862267
01 Jan 232,491890837254
30 Sep 222,9191,207843240
30 Jun 223,0411,325839222
31 Mar 222,7941,249750194
01 Jan 222,6751,197736174
30 Sep 212,4171,111665129
30 Jun 212,2691,055634101
31 Mar 212,15197463889
31 Dec 201,95187558881
30 Sep 201,77678058769
30 Jun 201,64370655769
31 Mar 201,51662654167
31 Dec 191,43257153968
30 Sep 191,29051448262
30 Jun 191,21949844756
31 Mar 191,10544241450
31 Dec 181,01740238846
30 Sep 1892538733841
30 Jun 1884634530447
31 Mar 1877731529036
31 Dec 1771828427727
30 Sep 1766226624617
30 Jun 176122512400
31 Mar 175662152250
31 Dec 165442022200
30 Sep 165372042150
30 Jun 165472092170
31 Mar 165322102080
31 Dec 155092001940
31 Dec 143711601390
31 Dec 133041271090

Quality Earnings: 300529 has high quality earnings.

Growing Profit Margin: 300529's current net profit margins (25.1%) are lower than last year (31.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300529's earnings have grown by 2.7% per year over the past 5 years.

Accelerating Growth: 300529's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300529 had negative earnings growth (-30.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (0.09%).


Return on Equity

High ROE: 300529's Return on Equity (15.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.